Biotron Ltd (bit) Logo

Biotron Ltd (BIT)

___:___ · Healthcare

BIT Chart


BIT's Principal Activity is the funding and management of intermediate and applied biotechnology research and development projects.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +0.40%
vs ASX 200 (1yr) -4.32%


Market Capitalisation
ASX Rank 1,297 of 2,375
Sector Rank 111 of 204

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies TDL / CHM / PAL
EPS -$0.005
DPS $0.00
NTA per share $0.01

Broker Consensus

BIT is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Biotron Limited (BIT) is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and a promising preclinical program for HBV. The technology targets viroporin proteins which enables the pathogenicity of several viruses including hepatitis C, HIV-1, Dengue, Zika viruses.

Incorporation Details

Incorporated In NSW on 23/02/1999

Corporate Details

Head Office North Ryde NSW 2113
Registry Computershare
Auditor KPMG
Date Listed 24 Jan 2001

Upcoming Calendar (Forecasted)

Date Event
22/02/2022 Report (Interim)
26/08/2022 Report (Prelim)
26/08/2022 Report (Annual)
19/10/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Professor Stephen Alister Locarnini Non-Executive Director Oct 2018 Director Bio icon

Professor Stephen Alister Locarnini

Non-Executive Director

Prof Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). He is a named inventor on over 20 internationally granted patents. He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. Professor Locarnini currently has an academic appointment at the University of Melbourne. He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic hepatitis B.

Mr Robert Bain Thomas Non-Executive Director Mar 2012 Director Bio icon

Mr Robert Bain Thomas

Non-Executive Director

Mr Thomas has over 35 years of experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Retail Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.

Dr Susan Margaret Pond Non-Executive Director Mar 2012 Director Bio icon

Dr Susan Margaret Pond

Non-Executive Director

Dr Pond has a scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as chairman and managing director of Johnson & Johnson Research Pty Limited (2003 - 2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia. Dr Pond is currently chair of the New South Wales Smart Sensing Network, director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd, Cannatrek Ltd and the Australian Phenomics Network and Governor in Council of the Queensland University of Technology.

Dr Michelle Miller Managing Director Jun 2002 Director Bio icon

Dr Michelle Miller

Managing Director

Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson & Johnson developing antiHIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a bioscience venture capital fund.

Mr Michael J Hoy Non-Executive Director,Non-Executive Chairman Feb 2000 Director Bio icon

Mr Michael J Hoy

Non-Executive Director,Non-Executive Chairman

Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.

Mr Peter James Nightingale Company Secretary Feb 1999

Director Transactions

BIT directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
22/01/20 Robert Thomas Buy +1,000,000 $0.05 $50,000 Off-market trade
10/01/20 Stephen Locarnini Buy +800,000 $0.05 $40,000 Off-market trade
10/01/20 Stephen Locarnini Buy +800,000 $0.05 $40,000 Off-market trade
23/12/19 Michelle Miller Issued 7,000,000 $0.055 $385,000 Issue of options
05/12/19 Susan Pond Buy +109,049 $0.05 $5,452 Exercise of options
05/12/19 Susan Pond Exercise 109,049 $0.05 $5,452 Exercise of options
05/12/19 Michelle Miller Transfer 1,500,000 $0.06 $90,000 Off-market transfer
05/12/19 Michelle Miller Buy +190,625 $0.05 $9,531 Exercise of options
05/12/19 Michelle Miller Exercise 190,625 $0.05 $9,531 Exercise of options
05/12/19 Michelle Miller Transfer 1,500,000 $0.06 $90,000 Off-market transfer
07/11/19 Michael Hoy Exercise 1,557,965 $0.05 $77,898 Exercise of options
07/11/19 Michael Hoy Buy +1,557,965 $0.05 $77,898 Exercise of options

Director Interests

The current holdings of BIT directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Stephen Locarnini 30/06/2021 N/A 800,000 N/A N/A
Susan Pond 30/06/2021 N/A 654,295 N/A N/A
Michelle Miller 30/06/2021 1,656,250 1,500,000 7,000,000 N/A
Robert Thomas 30/06/2021 N/A 3,663,195 N/A N/A
Michael Hoy 30/06/2021 N/A 9,347,793 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jul 31, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Jey Investment Pty Ltd 14,440,945 2.06%
Dr Angela Fay Dulhunty 10,000,000 1.42%
Umbiram Pty Ltd <Michael Hoy Super Fund A/C> 9,347,793 1.33%
Citicorp Nominees Pty Limited 8,427,055 1.20%
Jimmy Thomas and Ivy Ruth Ponniah 8,372,057 1.19%
DNS Accounting and Law Consultancy Pty Ltd 8,254,558 1.18%
Armco Barriers Pty Ltd 7,000,000 1.00%
Fordholm Investments Pty Ltd <Fordholm Super Fund A/C> 7,000,000 1.00%
Rookharp Capital Pty Limited 7,000,000 1.00%
Pathold No 222 Pty Ltd 5,250,000 0.75%
Scott s A V Pty Ltd <Scotts Acorn EMP S/F A/C> 4,918,000 0.70%
Edstop Pty Limited <Superannuation Fund A/C> 4,571,588 0.65%
William John Dunn 4,400,000 0.63%
Attollo Copia Pty Ltd <F A Pires Super Fund A/C> 4,300,565 0.61%
Travis Paul Gloury 3,779,784 0.54%
Robert Thomas and Kyrenia Thomas <Rob Thomas Super Fund A/C> 3,663,195 0.52%
Dr Sanjiv Pathak 3,632,313 0.52%
Peter James Nightingale 3,594,903 0.51%
Alpha Matilda Trading Pty Ltd <Alpha Matilda Superfund A/C> 3,337,472 0.48%
Mark Andrew Peterson 3,332,000 0.47%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 197 1,121 1,258 3,085 1,048 6,709

Substantial Shareholders

No Substantial Shareholders for BIT in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.074 30 June
2019 $0.066 28 June
2018 $0.019 29 June
2017 $0.02 28 June
2016 $0.06 28 June
2015 $0.125 30 June
2014 $0.105 30 June
Page Icon
BIT Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.